Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Treatment of an Advanced NSCLC Patient with a Rare OSBPL9-ALK Fusion: A Case Report. Local targets link to admitted publications; unresolved targets remain external evidence.
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
2024 · External reference
KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors
10.1056/nejmoa1917239 · 2020 · External reference
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
10.1038/s41392-019-0038-9 · 2019 · External reference
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
10.1056/nejmoa2202170 · 2022 · External reference
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
10.1056/nejmoa040938 · 2004 · External reference
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
10.1038/nature05945 · 2007 · External reference
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
10.1016/j.cell.2007.11.025 · 2007 · External reference
Genotype-driven therapies for non-small cell lung cancer: Focus on EGFR, KRAS and ALK gene abnormalities
10.1177/1758834010397569 · 2011 · External reference
ROS1-positive non-small cell lung cancer (NSCLC): Biology, diagnostics, therapeutics and resistance
10.1080/1061186x.2022.2085730 · 2022 · External reference
Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: A narrative review
10.21037/tlcr-22-566 · 2023 · External reference
EML4-ALK fusion gene in lung cancer and its biological function
2012 · External reference
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer
10.1158/1078-0432.ccr-08-3248 · 2009 · External reference
SMPD3-ALK: A novel ALK fusion gene in lung adenocarcinoma
10.1111/cge.13891 · 2021 · External reference
Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma
10.1016/j.lungcan.2024.107797 · 2024 · External reference
Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
10.3390/curroncol29100618 · 2022 · External reference
Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers
10.1186/s12967-021-02982-4 · 2021 · External reference
An advanced NSCLC patient with ALK-RNF144A and HIP1-ALK fusions treated with ALK-TKI combination therapy: A case report
10.21037/tlcr-23-656 · 2023 · External reference
10.20944/preprints202502.0162.v1
10.20944/preprints202502.0162.v1 · External reference
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
10.1200/jco.18.02236 · 2019 · External reference
Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management
10.1038/s41571-022-00639-9 · 2022 · External reference
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial
10.1001/jamaoncol.2021.3523 · 2021 · External reference
Efficacy and safety of ensartinib in the treatment of non-small cell lung cancer: A systematic review of clinical trials
2025 · External reference
Dramatic Response to Ensartinib in Metastatic Neuroendocrine Tumors With a Novel CEP44-ALK Fusion: A Case Report and Literature Review
10.1111/crj.70040 · 2024 · External reference
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
10.1002/cac2.12524 · 2024 · External reference
Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
10.2147/cmar.s283199 · 2022 · External reference
10.3389/fonc.2025.1594072
10.3389/fonc.2025.1594072 · External reference
Ensartinib vs Crizotinib for Patients With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial
10.1001/jamaoncol.2021.3523 · ExternalCitation · doi-reference
Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib-refractory ALK-positive NSCLC from a phase II study
10.1002/cac2.12524 · ExternalCitation · doi-reference
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
10.1016/j.cell.2007.11.025 · ExternalCitation · doi-reference
Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma
10.1016/j.lungcan.2024.107797 · ExternalCitation · doi-reference
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
10.1038/nature05945 · ExternalCitation · doi-reference
Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer
10.1038/s41392-019-0038-9 · ExternalCitation · doi-reference
Third-generation EGFR and ALK inhibitors: Mechanisms of resistance and management
10.1038/s41571-022-00639-9 · ExternalCitation · doi-reference
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
10.1056/nejmoa040938 · ExternalCitation · doi-reference
KRAS(G12C) Inhibition with Sotorasib in Advanced Solid Tumors
10.1056/nejmoa1917239 · ExternalCitation · doi-reference
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
10.1056/nejmoa2202170 · ExternalCitation · doi-reference
ROS1-positive non-small cell lung cancer (NSCLC): Biology, diagnostics, therapeutics and resistance
10.1080/1061186x.2022.2085730 · ExternalCitation · doi-reference
SMPD3-ALK: A novel ALK fusion gene in lung adenocarcinoma
10.1111/cge.13891 · ExternalCitation · doi-reference
Dramatic Response to Ensartinib in Metastatic Neuroendocrine Tumors With a Novel CEP44-ALK Fusion: A Case Report and Literature Review
10.1111/crj.70040 · ExternalCitation · doi-reference
KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer
10.1158/1078-0432.ccr-08-3248 · ExternalCitation · doi-reference
Genotype-driven therapies for non-small cell lung cancer: Focus on EGFR, KRAS and ALK gene abnormalities
10.1177/1758834010397569 · ExternalCitation · doi-reference
Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers
10.1186/s12967-021-02982-4 · ExternalCitation · doi-reference
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer
10.1200/jco.18.02236 · ExternalCitation · doi-reference
10.20944/preprints202502.0162.v1
10.20944/preprints202502.0162.v1 · ExternalCitation · doi-reference
Clinical characteristics and targeted therapy of different gene fusions in non-small cell lung cancer: A narrative review
10.21037/tlcr-22-566 · ExternalCitation · doi-reference
An advanced NSCLC patient with ALK-RNF144A and HIP1-ALK fusions treated with ALK-TKI combination therapy: A case report
10.21037/tlcr-23-656 · ExternalCitation · doi-reference
Update on Lorlatinib: Role in Reducing the Risk of Disease Progression in ALK-Positive NSCLC
10.2147/cmar.s283199 · ExternalCitation · doi-reference
10.3389/fonc.2025.1594072
10.3389/fonc.2025.1594072 · ExternalCitation · doi-reference
Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
10.3390/curroncol29100618 · ExternalCitation · doi-reference
